中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

601 records (took 0.024 seconds)

    HUMAN RECEPTOR H4-1BB
    44.
    发明专利
    HUMAN RECEPTOR H4-1BB 未知

    公开(公告)号：CA2172165A1

    公开(公告)日：1995-03-23

    申请号：CA2172165

    申请日：1994-09-15

    Applicant: INDIANA UNIVERSITY FOUNDATION

    Inventor： KWON BYOUNG S

    IPC: G01N33/53 ,  A61K38/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K16/28 ,  C12N5/10 ,  C12N5/12 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12P21/08 ,  G01N33/566 ,  G01N33/577 ,  A61K38/17 ,  C07K14/71 ,  C12N5/02 ,  C12N15/62 ,  C12Q1/42

    Abstract: The human receptor H4-1BB has been isolated, sequenced and disclosed herein. The cDNA of the human receptor H4-1BB is about 65 % homologous to the mouse cDNA 4-1BB and was isolated by using probes derived from cDNA 4-1BB. A fusion protein for detecting cell membrane ligands to human receptor protein H4-1BB was developed. It comprises the extracellular portion of the receptor protein H4-1BB and a detection protein (alkaline phosphatase) bound to the portion of the receptor protein H4-1BB. B-cells that have expressed a ligand to receptor protein H4-1BB can be treated with cells that have expressed receptor protein H41BB and B-cell proliferation may be induced. The use of H4-1BB to block H41BB ligand binding has practical application in the suppression of the immune system during organ transplantation. A monoclonal antibody against H4-1BB can be used to enhance T-cell proliferation by treating T-cells that have expressed receptor protein H4-1BB with the anti H4-1BB monoclonal antibody. Tumors transfected with H4-1BBL may be capable of delivering antigen-specific signals as well as the co-stimulatory signals and can be killed by human cytotoxic T lymphocytes.

    46.
    发明专利
    未知

    公开(公告)号：IT1249720B

    公开(公告)日：1995-03-09

    申请号：ITRM910812

    申请日：1991-10-25

    Applicant: INDIANA UNIVERSITY FOUNDATION

    Inventor： NOVOTNY MILOS V ,  DOLNIK VLADISLAV ,  COBB KELLY A

    IPC: C08F2/10 ,  C08F4/30 ,  G01N27/447 ,  C23B

    Abstract: Gels are formed in capillary tubes by electrophoretically drawing a charged polymerization initiator into a capillary tube pre-filled with monomer, crosslinking agent and catalyst. The rate of travel of the initiator is slow enough to maintain a sharp leading edge or front, thereby causing polymerization to occur in a progressive manner from one end of the capillary to the other. The shrinkage inherent in the polymerization reaction is thus compensated by fluid movement ahead of the traveling initiator front, and discontinuities in the gel which would otherwise be formed are avoided.

    MAMMALIAN PHOSPHOLIPASE A2 NUCLEOTIDE SEQUENCES, LOW MOLECULAR WEIGHT AMINO ACID SEQUENCES ENCODED THEREBY, ANTISENSE SEQUENCES AND NUCLEOTIDE SEQUENCES HAVING INTERNAL RIBOSOME BINDING SITES
    47.
    发明专利
    MAMMALIAN PHOSPHOLIPASE A2 NUCLEOTIDE SEQUENCES, LOW MOLECULAR WEIGHT AMINO ACID SEQUENCES ENCODED THEREBY, ANTISENSE SEQUENCES AND NUCLEOTIDE SEQUENCES HAVING INTERNAL RIBOSOME BINDING SITES 未知

    公开(公告)号：CA2167296A1

    公开(公告)日：1995-01-26

    申请号：CA2167296

    申请日：1994-07-15

    Applicant: INDIANA UNIVERSITY FOUNDATION ,  INCYTE PHARMA INC

    Inventor： TISCHFIELD JAY A ,  SEILHAMER JEFFREY J

    IPC: C12N9/16 ,  C12N15/55 ,  A01K67/027 ,  A61K31/70 ,  A61K48/00 ,  C12N5/10 ,  C12N9/20 ,  C12N15/62

    Abstract: Novel mammalian phospholipase (PLA2) nucleotide sequences and low molecular weight (about 14 KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned h= HPLA2 cDNA expressing HPLA2-10 and its cloned rat RPLA2 cDNA counterpart, expressing RPLA2-10, which are characterized as PLA2 Type IV, are disclosed. A second type of PLA2 cDNA, characterized as PLA2 Type III and exemplified by a rat PLA2 cDNA encoding RPLA2-8 and a partial h= PLA2 nucleotide sequence encoding HPLA2-8, is disclosed. Expression of the cDNAs encode she two new types of PLA2 enzymes which have phospholipase activity. The novel PLA2s do not include disutfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA2s may include amino acid COOH-terminal extensions which can vary in length. Seventeen of the eighteen absolutely conserved amino acids in all active 14 KD PLA2s are believed to be conserved in RPLA2-8 and HPLA2-8, whereas all eighteen are believed to be conserved in RPLA2-10 and HPLA2-10. Because the encoded sequences of RPLA2-8 and HPLA2-8 include only 16 cysteine amino acids, they have been designated as Type III. RPLA2-10 and HPLA2-10 are designated as Type IV since their encoded sequences include only 12 cysteine amino acids.

    Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
    48.
    发明专利
    Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin 未知

    公开(公告)号：AU6782794A

    公开(公告)日：1994-12-12

    申请号：AU6782794

    申请日：1994-05-05

    Applicant: INDIANA UNIVERSITY FOUNDATION

    Inventor： WEBER GEORGE

    IPC: A61K31/70 ,  A61K20060101 ,  A61K31/00 ,  A61P35/00

    Abstract: The present invention relates to the treatment of neoplastic disease in warm blooded animals using the sequential administration of tiazofurin and ribavirin. Tiazofurin is administered first in a high dose in order to facilitate a sharp decrease in IMP DH activity. These gains are consolidated by the continual administration of tiazofurin until the hematological levels have stabilized and remission is achieved. Once the patient is in remission, ribavirin is administered in steadily tapering dosages until the minimum dosage that will retain the beneficial effect of the tiazofurin is achieved. The IMP DH activity, GTP concentration, and hematological data is continually monitored throughout the treatment and dosages adjusted.

    Automatic fibrillation detector and defibrillator apparatus and method
    50.
    发明专利
    Automatic fibrillation detector and defibrillator apparatus and method 未知

    公开(公告)号：AU4769193A

    公开(公告)日：1994-01-24

    申请号：AU4769193

    申请日：1993-06-25

    Applicant: INDIANA UNIVERSITY FOUNDATION

    Inventor： ZIPES DOUGLAS P ,  ADAMS DAVID E

    IPC: A61N1/39

    Abstract: The present invention involves an apparatus and method for detecting and treating fibrillation in the heart. Electrodes sense electrical activity in two distinct locations of the heart. The electrocardiac activations are monitored and the interval between activations at the two locations is measured and checked for variation. Upon detection of significant variation in the length of the intervals, the fibrillation condition is determined and a defibrillator is activated, so that a defibrillating shock may be delivered to the heart. For atrial fibrillation, the first defibrillating shock is relatively low and is increased until the fibrillation is no longer detected.

Patent Agency Ranking